PROMIS NEUROSCIENCES INC. Comprehensive Income
PROMIS NEUROSCIENCES INC. (PMN) reported Comprehensive Income of $2.78 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2025-03-31
- PROMIS NEUROSCIENCES INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-12-31 was -$238.21K.
- PROMIS NEUROSCIENCES INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-09-30 was $9.28M.
- PROMIS NEUROSCIENCES INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-06-30 was -$2.62M.
- PROMIS NEUROSCIENCES INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-03-31 was -$3.64M.
- PROMIS NEUROSCIENCES INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $2.78M.
- PROMIS NEUROSCIENCES INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$13.21M.
- PROMIS NEUROSCIENCES INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$18.07M.
- PROMIS NEUROSCIENCES INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$9.93M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$238.21K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $9.04M derived: sum of 2 quarters · filed 2025-03-31 | $6.41M derived: sum of 3 quarters · filed 2025-03-31 | $2.78M 10-K · filed 2025-03-31 |
| 2024-09-30 | $9.28M 10-Q · filed 2024-11-14 | $6.65M derived: sum of 2 quarters · filed 2024-11-14 | $3.02M 10-Q · filed 2024-11-14 | -$387.53K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | -$2.62M 10-Q · filed 2024-08-08 | -$6.26M 10-Q · filed 2024-08-08 | -$9.66M derived: sum of 3 quarters · filed 2025-03-31 | -$12.02M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | -$3.64M 10-Q · filed 2024-05-14 | -$7.04M derived: sum of 2 quarters · filed 2025-03-31 | -$9.40M derived: sum of 3 quarters · filed 2025-03-31 | -$11.88M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | -$3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$5.77M derived: sum of 2 quarters · filed 2025-03-31 | -$8.25M derived: sum of 3 quarters · filed 2025-03-31 | -$13.21M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$2.36M 10-Q · filed 2024-11-14 | -$4.84M derived: sum of 2 quarters · filed 2024-11-14 | -$9.81M 10-Q · filed 2024-11-14 | -$17.00M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$2.48M 10-Q · filed 2024-08-08 | -$7.45M 10-Q · filed 2024-08-08 | -$14.64M derived: sum of 3 quarters · filed 2024-08-08 | -$20.73M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$4.96M 10-Q · filed 2024-05-14 | -$12.15M derived: sum of 2 quarters · filed 2024-05-14 | -$18.24M derived: sum of 3 quarters · filed 2024-05-14 | -$20.99M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$13.28M derived: sum of 2 quarters · filed 2024-04-01 | -$16.02M derived: sum of 3 quarters · filed 2024-04-01 | -$18.07M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$6.09M 10-Q · filed 2023-11-14 | -$8.83M derived: sum of 2 quarters · filed 2023-11-14 | -$10.88M 10-Q · filed 2023-11-14 | -$13.16M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$2.74M 10-Q · filed 2023-08-14 | -$4.79M 10-Q · filed 2023-08-14 | -$7.07M derived: sum of 3 quarters · filed 2023-08-14 | -$8.24M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$2.05M 10-Q · filed 2023-05-15 | -$4.33M derived: sum of 2 quarters · filed 2023-05-15 | -$5.49M derived: sum of 3 quarters · filed 2023-05-15 | -$5.81M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$3.45M derived: sum of 2 quarters · filed 2023-03-08 | -$3.76M derived: sum of 3 quarters · filed 2023-03-08 | -$9.93M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$1.17M 10-Q · filed 2022-11-14 | -$1.49M derived: sum of 2 quarters · filed 2022-11-14 | -$7.65M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$317.38K 10-Q · filed 2022-08-12 | -$6.48M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |